{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:09:32Z","timestamp":1793189372815,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2016CDF-1555"],"award-info":[{"award-number":["TMA2016CDF-1555"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primaquine is a pro-drug and its active metabolite is potent against mature <jats:italic>Plasmodium falciparum<\/jats:italic> gametocytes. Primaquine is metabolized by a highly polymorphic cytochrome P450 2D6 (CYP2D6)\u00a0enzyme. Mutations in the gene encoding this enzyme may lead to impaired primaquine activity. This study assessed if 0.25\u00a0mg\/kg single-dose primaquine is safe and sufficient to reduce transmission of gametocytes in individuals with no, reduced, or increased CYP2D6 enzyme activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Between June 2019 and January 2020 children aged 1\u201310\u00a0years, attending at Yombo dispensary, Bagamoyo district, with confirmed microcopy-determined uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria were enrolled in the study. The enrolled patients were treated with a standard artemether-lumefantrine regimen plus 0.25\u00a0mg\/kg single-dose primaquine and followed up for 28\u00a0days for clinical and laboratory assessment. Primaquine was administered with the first dose of artemether-lumefantrine. Safety assessment involved direct questioning and recording of the nature and incidence of clinical signs and symptoms, and measurement of haemoglobin (Hb) concentration. Blood samples collected from 100 patients were used for assessment of post-treatment infectiousness on day 7 using mosquito membrane feeding assays. Molecular methods were used to determine CYP2D6 and glucose-6-phosphate dehydrogenase (G6PD) status. The primary outcome was the safety of 0.25\u00a0mg\/kg single-dose primaquine based on CYP2D6 status.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 157 children [median age 6.4 (Interquartile range 4.0\u20138.2) years] were recruited, of whom 21.0% (33\/157) and 12.7% (20\/157) had reduced CYP2D6 and deficient G6PD activity, respectively. Day 3 mean absolute Hb concentration reduction was 1.50\u00a0g\/dL [95% confidence interval (CI) 1.10\u20131.90] and 1.51\u00a0g\/dL (95% CI 1.31\u20131.71) in reduced and normal CYP2D6 patients, respectively (<jats:italic>t<\/jats:italic>\u2009=\u20090.012, <jats:italic>p<\/jats:italic>\u2009=\u20090.990). The day 3 mean absolute Hb concentration reduction in G6PD deficient, G6PD normal and heterozygous female was 1.82\u00a0g\/dL (95% CI 1.32\u20132.32), 1.48\u00a0g\/dL (95% CI 1.30\u20131.67) and 1.47\u00a0g\/dL (95% CI 0.76\u20132.18), respectively (<jats:italic>F<\/jats:italic>\u2009=\u20090.838, <jats:italic>p<\/jats:italic>\u2009=\u20090.435). Sixteen percent (16\/98) of the patients each infected at least one mosquito on day 7, and of these, 10.0% (2\/20) and 17.9% (14\/78) had reduced and normal CYP2D6 enzyme activity, respectively (<jats:italic>x<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u20090.736, <jats:italic>p<\/jats:italic>\u2009=\u20090.513).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Single-dose 0.25\u00a0mg\/kg primaquine was safe and sufficient for reducing transmission of <jats:italic>P. falciparum<\/jats:italic> gametocytes regardless of CYP2D6 or G6PD status.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Study registration number: NCT03352843.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04100-1","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T11:02:46Z","timestamp":1647082966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1341-4304","authenticated-orcid":false,"given":"Richard Owden","family":"Mwaiswelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Billy","family":"Ngasala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Msolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliningaya","family":"Kweka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno P.","family":"Mmbando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"M\u00e5rtensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"4100_CR1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/1475-2875-11-360","volume":"11","author":"AC Eziefula","year":"2012","unstructured":"Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, von Seidlein L, et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J. 2012;11:360.","journal-title":"Malar J"},{"key":"4100_CR2","volume-title":"World malaria report 2020","author":"WHO","year":"2020","unstructured":"WHO. World malaria report 2020. Geneva: World Health Organization; 2020."},{"key":"4100_CR3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40249-016-0151-8","volume":"5","author":"RE Cibulskis","year":"2016","unstructured":"Cibulskis RE, Alonso P, Aponte J, Aregawi M, Barrette A, Bergeron L, et al. Malaria: global progress 2000\u20132015 and future challenges. Infect Dis Poverty. 2016;5:61.","journal-title":"Infect Dis Poverty"},{"key":"4100_CR4","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"4100_CR5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"A Dondorp","year":"2009","unstructured":"Dondorp A, Nosten F, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"4100_CR6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/657120","volume":"51","author":"H Noedl","year":"2010","unstructured":"Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010;51:82\u20139.","journal-title":"Clin Infect Dis"},{"key":"4100_CR7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"E Ashley","year":"2014","unstructured":"Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"4100_CR8","volume-title":"Malaria vector control and personal protection","author":"WHO","year":"2006","unstructured":"WHO. Malaria vector control and personal protection. Geneva: World Health Organization; 2006."},{"key":"4100_CR9","volume-title":"Global malaria control and elimination","author":"WHO","year":"2008","unstructured":"WHO. Global malaria control and elimination. Geneva: World Health Organization; 2008."},{"key":"4100_CR10","volume-title":"Universal access to core malaria interventions in high-burden countries","author":"WHO","year":"2018","unstructured":"WHO. Universal access to core malaria interventions in high-burden countries. Geneva: World Health Organization; 2018."},{"key":"4100_CR11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1475-2875-13-51","volume":"13","author":"A Kondrashin","year":"2014","unstructured":"Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13:51.","journal-title":"Malar J"},{"key":"4100_CR12","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/424663","volume":"39","author":"JK Baird","year":"2004","unstructured":"Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336\u201345.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4100_CR13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejmech.2008.08.011","volume":"44","author":"N Vale","year":"2009","unstructured":"Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem. 2009;44(3):937\u201353.","journal-title":"Eur J Med Chem"},{"key":"4100_CR14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:351.","journal-title":"Malar J"},{"key":"4100_CR15","first-page":"CD008152","volume":"9","author":"PM Graves","year":"2012","unstructured":"Graves PM, Gelband H, Garner P. Primaquine for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2012;9:CD008152.","journal-title":"Cochrane Database Syst Rev"},{"key":"4100_CR16","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-13-418","volume":"13","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.","journal-title":"Malar J"},{"key":"4100_CR17","volume-title":"Proposal for an evidence review group (ERG) on G6PD testing to support increased access to primaquine for radical cure of Plasmodium vivax and for malaria chemoprophylaxis","author":"WHO","year":"2013","unstructured":"WHO. Proposal for an evidence review group (ERG) on G6PD testing to support increased access to primaquine for radical cure of Plasmodium vivax and for malaria chemoprophylaxis. Geneva: World Health Organization; 2013."},{"key":"4100_CR18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-11-418","volume":"11","author":"NJ White","year":"2012","unstructured":"White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocidal in populations where G6PD deficiency is common. Malar J. 2012;11:418.","journal-title":"Malar J"},{"key":"4100_CR19","volume-title":"Safety of 8-aminoquinoline antimalarial medicines","author":"J Recht","year":"2014","unstructured":"Recht J, Ashley E, White N. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014."},{"key":"4100_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa498","author":"K Stepniewska","year":"2020","unstructured":"Stepniewska K, Humphreys GS, Gon\u00e7alves BP, Craig E, Gosling R, Guerin PJ, et al. Efficacy of single-dose primaquine with artemisinin combination therapy on Plasmodium falciparum gametocytes and transmission: an individual patient meta-analysis. J Infect Dis. 2020. https:\/\/doi.org\/10.1093\/infdis\/jiaa498.","journal-title":"J Infect Dis"},{"key":"4100_CR21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1473-3099(13)70268-8","volume":"14","author":"AC Eziefula","year":"2014","unstructured":"Eziefula AC, Bousema T, Yeung S, Kamya M, Owaraganise A, Gabagaya G, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomized, controlled, double-blind, dose-ranging trial. Lancet Infect Dis. 2014;14:130\u20139.","journal-title":"Lancet Infect Dis"},{"key":"4100_CR22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S1473-3099(15)00479-X","volume":"16","author":"A Dicko","year":"2016","unstructured":"Dicko A, Brown JM, Diawara H, Baber I, Mahamar A, Soumare HM, et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomized phase 2 trial. Lancet Infect Dis. 2016;16:674\u201384.","journal-title":"Lancet Infect Dis"},{"key":"4100_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","volume":"14","author":"BP Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves BP, Tiono AB, Ou\u00e9draogo A, Guelb\u00e9ogo WM, Bradley J, Nebie I, et al. Single low-dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:40.","journal-title":"BMC Med"},{"key":"4100_CR24","doi-asserted-by":"crossref","first-page":"e0151898","DOI":"10.1371\/journal.pone.0151898","volume":"11","author":"G Bancone","year":"2016","unstructured":"Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, et al. Single low-dose primaquine (0.25mg\/kg) does not cause clinically significant hemolysis in G6PD deficient subjects. PLoS ONE. 2016;11:e0151898.","journal-title":"PLoS ONE"},{"key":"4100_CR25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12936-016-1341-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala BE, Jovel I, Gosling R, Premji Z, Poirot E, et al. Safety of a single low-dose of primaquine in addition to the standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. Malar J. 2016;15:316.","journal-title":"Malar J"},{"key":"4100_CR26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/1475-2875-11-259","volume":"11","author":"BS Pybus","year":"2012","unstructured":"Pybus BS, Sousa JC, Jin X, Ferguson JA, Christian RE, Barnhart R, et al. CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine. Malar J. 2012;11:259.","journal-title":"Malar J"},{"key":"4100_CR27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/1475-2875-12-212","volume":"12","author":"BS Pybus","year":"2013","unstructured":"Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12:212.","journal-title":"Malar J"},{"key":"4100_CR28","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1128\/AAC.00015-15","volume":"59","author":"BMJ Potter","year":"2015","unstructured":"Potter BMJ, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, et al. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59:2380\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"4100_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","volume":"161","author":"SR Marcsisin","year":"2016","unstructured":"Marcsisin SR, Reichard G, Pybus BS. Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther. 2016;161:1\u201310.","journal-title":"Pharmacol Ther"},{"key":"4100_CR30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/emph\/eot010","volume":"2013","author":"RK Bains","year":"2013","unstructured":"Bains RK. African variation at cytochrome P450 genes: evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health. 2013;2013:118\u201334.","journal-title":"Evol Med Public Health"},{"key":"4100_CR31","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/1475-2875-13-488","volume":"13","author":"RJH Ingram","year":"2014","unstructured":"Ingram RJH, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malar J. 2014;13:488.","journal-title":"Malar J"},{"key":"4100_CR32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows a high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93\u2013101.","journal-title":"Pharmacogenet Genomics"},{"key":"4100_CR33","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FPC.0b013e32832e0e97","volume":"19","author":"RP Owen","year":"2009","unstructured":"Owen RP, Sangkuhl K, Klein TE, Altman RB. Cytochrome P450 2D6. Pharmacogenet Genomics. 2009;19:559\u201362.","journal-title":"Pharmacogenet Genomics"},{"key":"4100_CR34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven LJ. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19:69\u201376.","journal-title":"Genet Med"},{"key":"4100_CR35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s002280100282","volume":"57","author":"C Dandara","year":"2001","unstructured":"Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, De Sommers K, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in East- and Southern African populations including psychiatric patients. Eur J Clin Pharmacol. 2001;57:11\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"4100_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1475-2875-13-S1-P69","volume":"13","author":"H Pett","year":"2014","unstructured":"Pett H, Drakeley C, Eziefula A, Neuvonen M, Lanke K, Sauerwein R, et al. CYP2D6 intermediate metabolizer status could slow down Plasmodium falciparum gametocyte clearance after single-dose primaquine. Malar J. 2014;13:31.","journal-title":"Malar J"},{"key":"4100_CR37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/1475-2875-13-483","volume":"13","author":"NJ White","year":"2014","unstructured":"White NJ, Ashley EA, Recht J, Delves MJ, Ruecker A, Smithuis FM, et al. Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malar J. 2014;13:483.","journal-title":"Malar J"},{"key":"4100_CR38","doi-asserted-by":"crossref","first-page":"e76316","DOI":"10.1371\/journal.pone.0076316","volume":"8","author":"R Wampfler","year":"2013","unstructured":"Wampfler R, Mwingira F, Javati S, Robinson L, Betuela I, Siba P, et al. Strategies for detection of Plasmodium species gametocytes. PLoS ONE. 2013;8:e76316.","journal-title":"PLoS ONE"},{"key":"4100_CR39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/JCM.43.1.402-405.2005","volume":"43","author":"P Schneider","year":"2005","unstructured":"Schneider P, Wolters L, Schoone G, Schallig H, Sillekens P, Hermsen R, et al. Real-time nucleic acid sequence-based amplification is more convenient than real-time PCR for quantification of Plasmodium falciparum. J Clin Microbiol. 2005;43:402\u20135.","journal-title":"J Clin Microbiol"},{"key":"4100_CR40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.pt.2008.08.001","volume":"24","author":"HA Babiker","year":"2008","unstructured":"Babiker HA, Schneider P, Reece SE. Gametocytes: insights gained during a decade of molecular monitoring. Trends Parasitol. 2008;24:525\u201330.","journal-title":"Trends Parasitol"},{"key":"4100_CR41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4314\/thrb.v13i3.66915","volume":"13","author":"B Kabula","year":"2011","unstructured":"Kabula B, Derua Y, Tungu P, Massue DJ, Sambu E, Stanley G, et al. Malaria entomological profile in Tanzania from 1950 to 2010: a review of mosquito distribution, vectorial capacity, and insecticide resistance. Tanzan J Health Res. 2011;13:319\u201331.","journal-title":"Tanzan J Health Res"},{"key":"4100_CR42","unstructured":"National Malaria Control Programme. Malaria surveillance bulletin-2017. Dodoma, Tanzania 2018."},{"key":"4100_CR43","unstructured":"National Malaria Control Programme. Tanzania malaria programme review 2010. Program Review proposal. Dar es Salaam, Tanzania. 2010."},{"key":"4100_CR44","unstructured":"National Malaria Control Programme. National guidelines for malaria diagnosis, treatment and preventive therapies 2020. Dodoma, Tanzania. 2020."},{"key":"4100_CR45","unstructured":"National Malaria Control Programme. National malaria strategic plan 2014\u20132020. Dar es Salaam. Tanzania. 2014."},{"key":"4100_CR46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mcp.2002.120239","volume":"71","author":"A Wennerholm","year":"2002","unstructured":"Wennerholm A, Dandara C, Sayi J, Svensson JO, Abdi YA, Ingelman-Sundberg M, et al. The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther. 2002;71:77\u201388.","journal-title":"Clin Pharmacol Ther"},{"key":"4100_CR47","unstructured":"Poirot E, Hwang J, Brown J, Gosling R. A safety-monitoring tool for primaquine use to reduce transmission of Plasmodium falciparum. In: poster presentation for the 62nd American Society of Tropical Medicine and Hygiene annual conference. 2013."},{"key":"4100_CR48","unstructured":"EMA. Guideline for good clinical practice E6 (R2). Vol. 6, European Medicines Agency. 2016."},{"key":"4100_CR49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552\u20139.","journal-title":"N Engl J Med"},{"key":"4100_CR50","unstructured":"Urbaniak GC, Plous S. Research randomizer (version 4.0) [Computer software]. http:\/\/www.randomizer.org\/. Accessed 22 June 2013."},{"key":"4100_CR51","unstructured":"Zymo Research. Quick DNA miniprep plus kit. 2021. http:\/\/www.zymoresearch.com\/dna\/genomic-dna\/cell-soft-tissue-dna\/quick-dna-miniprep-plus-kit. Accessed 15 July 2021."},{"key":"4100_CR52","unstructured":"Agena Bioscience. Sample identification for VeriDose CNV analysis. https:\/\/www.veritastk.co.jp\/products\/pdf\/PGx_WhitePaper_2N Sample Identification.pdf. Accessed 15 July 2021."},{"key":"4100_CR53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12936-020-03326-1","volume":"19","author":"A Martin Ram\u00edrez","year":"2020","unstructured":"Martin Ram\u00edrez A, Lombardia Gonz\u00e1lez C, Soler Maniega T, Gutierrez Liarte \u00c1, Domingo Garc\u00eda D, Lanza Su\u00e1rez M, et al. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. Malar J. 2020;19:259.","journal-title":"Malar J"},{"key":"4100_CR54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1475-2875-10-241","volume":"10","author":"N Carter","year":"2011","unstructured":"Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J. 2011;10:241.","journal-title":"Malar J"},{"key":"4100_CR55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0035-9203(99)90120-7","volume":"2","author":"G Snounou","year":"1999","unstructured":"Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, Brown K, et al. Biased distribution of msp1 populations in Thailand and msp2 allelic variants in Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1999;2:369\u201374.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4100_CR56","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1475-2875-7-248","volume":"7","author":"M Diallo","year":"2008","unstructured":"Diallo M, Toure AM, Traore SF, Niare O, Kassambara L, Konare A, et al. Evaluation and optimization of membrane feeding compared to direct feeding as an assay for infectivity. Malar J. 2008;7:248.","journal-title":"Malar J"},{"key":"4100_CR57","doi-asserted-by":"crossref","first-page":"e0042821","DOI":"10.1371\/journal.pone.0042821","volume":"7","author":"T Bousema","year":"2012","unstructured":"Bousema T, Dinglasan RR, Morlais I, Gouagna LC, van Warmerdam T, Awono-Ambene PH, et al. Mosquito feeding assays to determine the infectiousness of naturally infected Plasmodium falciparum gametocyte carriers. PLoS ONE. 2012;7:e0042821.","journal-title":"PLoS ONE"},{"key":"4100_CR58","first-page":"16","volume":"4","author":"AL Ou\u00e9draogo","year":"2013","unstructured":"Ou\u00e9draogo AL, Guelb\u00e9ogo WM, Cohuet A, Morlais I, King JG, Gon\u00e7alves BP, et al. A protocol for membrane feeding assays to determine the infectiousness of P. falciparum naturally infected individuals to Anopheles gambiae. Malar World J. 2013;4:16.","journal-title":"Malar World J"},{"issue":"3","key":"4100_CR59","first-page":"397","volume":"59","author":"RS Grewal","year":"1981","unstructured":"Grewal RS. Pharmacology of 8-aminoquinolines. Bull World Health Organ. 1981;59(3):397\u2013406.","journal-title":"Bull World Health Organ"},{"key":"4100_CR60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1473-3099(12)70198-6","volume":"13","author":"NJ White","year":"2013","unstructured":"White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis. 2013;13:175\u201381.","journal-title":"Lancet Infect Dis"},{"key":"4100_CR61","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00538-19","volume":"63","author":"H Pett","year":"2019","unstructured":"Pett H, Bradley J, Okebe J, Dicko A, Tiono AB, Gon\u00e7alves BP, et al. CYP2D6 polymorphisms and the safety and gametocytocidal activity of single-dose primaquine for Plasmodium falciparum. Antimicrob Agents Chemother. 2019;63:10.","journal-title":"Antimicrob Agents Chemother"},{"key":"4100_CR62","first-page":"391","volume":"59","author":"DF Clyde","year":"1981","unstructured":"Clyde DF. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ. 1981;59:391\u20135.","journal-title":"Bull World Health Organ"},{"key":"4100_CR63","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4269\/ajtmh.2007.77.779","volume":"77","author":"E Beutler","year":"2007","unstructured":"Beutler E, Duparc S. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. Am J Trop Med Hyg. 2007;77:779\u201389.","journal-title":"Am J Trop Med Hyg"},{"key":"4100_CR64","doi-asserted-by":"crossref","first-page":"e0190272","DOI":"10.1371\/journal.pone.0190272","volume":"13","author":"GJH Bastiaens","year":"2018","unstructured":"Bastiaens GJH, Tiono AB, Okebe J, Pett HE, Coulibaly SA, Gon\u00e7alves BP, et al. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: two open-label, randomized, safety trials. PLoS ONE. 2018;13:e0190272.","journal-title":"PLoS ONE"},{"key":"4100_CR65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/cix355","volume":"65","author":"RC Tine","year":"2017","unstructured":"Tine RC, Sylla K, Faye BT, Poirot E, Fall FB, Sow D, et al. Safety and efficacy of adding a single low dose of primaquine to the treatment of adult patients with Plasmodium falciparum malaria in senegal, to reduce gametocyte carriage: a randomized controlled trial. Clin Infect Dis. 2017;65:535\u201343.","journal-title":"Clin Infect Dis"},{"key":"4100_CR66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12936-019-2841-8","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Allen E, Workman L, Mabuza A, Swanepoel H, Malatje G, et al. Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. Malar J. 2019;18:209.","journal-title":"Malar J"},{"key":"4100_CR67","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12879-017-2530-6","volume":"17","author":"J Zwang","year":"2017","unstructured":"Zwang J, D\u2019Alessandro U, Ndiaye JL, Djimd\u00e9 AA, Dorsey G, M\u00e5rtensson AA, et al. Haemoglobin changes and risk of anemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa. BMC Infect Dis. 2017;17:443.","journal-title":"BMC Infect Dis"},{"key":"4100_CR68","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0169-4758(00)01774-9","volume":"16","author":"C Menendez","year":"2000","unstructured":"Menendez C, Fleming AF, Alonso PL, Menendez C, Fleming A, Alonso P. Malaria-related anaemia. Parasitol Today. 2000;16:469\u201376.","journal-title":"Parasitol Today"},{"key":"4100_CR69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/asheducation-2009.1.87","volume":"574","author":"K Haldar","year":"2009","unstructured":"Haldar K, Mohandas N. Malaria, erythrocytic infection, and anemia. Hematol Am Soc Hematol Educ Progr. 2009;574:87\u201393.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"4100_CR70","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.7150\/ijbs.7.1427","volume":"7","author":"DJ Perkins","year":"2011","unstructured":"Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Michael J. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci. 2011;7:1427\u201342.","journal-title":"Int J Biol Sci"},{"key":"4100_CR71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/1475-2875-10-278","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. The parasite clearance curve. Malar J. 2011;10:278.","journal-title":"Malar J"},{"key":"4100_CR72","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/cid\/cir066","volume":"52","author":"BE Ngasala","year":"2011","unstructured":"Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis. 2011;52:873\u201382.","journal-title":"Clin Infect Dis"},{"key":"4100_CR73","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1186\/s12936-016-1430-3","volume":"15","author":"R Mwaiswelo","year":"2016","unstructured":"Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, et al. Adding a single low-dose of primaquine (0.25 mg\/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial. Malar J. 2016;15:435.","journal-title":"Malar J"},{"key":"4100_CR74","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1186\/1475-2875-13-376","volume":"13","author":"A Shayo","year":"2014","unstructured":"Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in. Malar J. 2014;13:376.","journal-title":"Malar J"},{"key":"4100_CR75","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12936-018-2524-x","volume":"17","author":"MA Kakolwa","year":"2018","unstructured":"Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018;17:369.","journal-title":"Malar J"},{"key":"4100_CR76","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2875-11-58","volume":"11","author":"E Kamugisha","year":"2012","unstructured":"Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, et al. Efficacy of artemether-lumefantrine in the treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza. Malar J. 2012;11:58.","journal-title":"Malar J"},{"key":"4100_CR77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12936-017-1712-4","volume":"16","author":"MM Plucinski","year":"2017","unstructured":"Plucinski MM, Dimbu PR, Macaia AP, Ferreira CM, Samutondo C, Quivinja J, et al. Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. Malar J. 2017;16:62.","journal-title":"Malar J"},{"key":"4100_CR78","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4269\/ajtmh.2006.74.991","volume":"74","author":"M Makanga","year":"2006","unstructured":"Makanga M, Premji Z, Falade C, Karbwang J, Mueller E, Andriano K, et al. Efficacy and safety of the six-dose regimen of artemether-lumefantrine in pediatrics with uncomplicated Plasmodium falciparum malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg. 2006;74:991\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"4100_CR79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-3305-3-1","volume":"3","author":"A Assefa","year":"2010","unstructured":"Assefa A, Kassa M, Tadese G, Mohamed H, Animut A, Mengesha T. Therapeutic efficacy of Artemether-Lumefantrine (Coartem \u00ae) against Plasmodium falciparum in Southwest Ethiopia. Parasit Vectors. 2010;3:1.","journal-title":"Parasit Vectors"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04100-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04100-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T11:19:03Z","timestamp":1647083943000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04100-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4100"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04100-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearances to conduct the trial were obtained from the Muhimbili University of Health and Allied Sciences Institutional Ethics Review Board (DA.282\/298\/01.C) and the National Health Research Ethics Review Committee of the National Institute for Medical Research (NIMR\/HQ\/R.8a\/Vol.IX\/2983). Written informed consent was obtained from parents\/guardians of the participants whereas children aged \u2265\u20097\u00a0years also provided assent before their enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they do not have any competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}